leadf
logo-loader
viewOrthocell Ltd

Orthocell publishes case study focusing on CelGro® collagen and Ortho-ATI® for surgical repairs

The case study has proven that CelGro®, combined with Ortho-ATI® is effective in returning a patient to normal function and has been published in the International Journal of Case Reports.

Orthocell Ltd -
The 63 year-old patient failed conservative and surgical treatment options suffering pain and disfunction over 15 years, prior to CelGro® plus Ortho-ATI® surgical treatment

Orthocell Ltd (ASX:OCC) has published a case study focusing on the combination of CelGro® collagen medical device and autologous tenocyte implantation (Ortho-ATI®) for the surgical repair of a large degenerate tear of the gluteal medius tendon. 

The case study was published by internationally recognised orthopaedic hip specialist surgeon Dr John M O’Donnell and sports and exercise doctor Professor Jane Fitzpatrick and supports Ortho-ATI® and CelGro® as durable, long term solutions for degenerate, treatment-resistant tendons that can be used on their own or in combination. 

This case report was designed to assess the role and effectiveness of CelGro® when combined with Ortho-ATI® to treat chronic degenerative gluteal tendinopathy in a 63-year-old woman. 

The patient suffered from chronic right-sided hip pain for over 15 years, which significantly affected her ability to sleep, work and exercise and underwent numerous conservative treatment options (including physiotherapy, load management, platelet-rich plasma and corticosteroid injection therapy) and right hip replacement surgery - all without success.

“Global first”

Managing director Paul Anderson said: “The positive case study is a global first supporting the combination of CelGro® and Ortho-ATI® to provide a durable solution to treat severely torn tendons.

“This is an exciting pipeline application combining our leading products CelGro® Ortho-ATI® and is a ground-breaking approach that continues to place OCC at the forefront of tendon regenerative medicine.”

The case report may be viewed here.

Ortho-ATI® plus CelGro® treatment process and results

The patient underwent open surgery in April 2017, where the gluteus medius was anatomically repaired.

CelGro®, acting as a carrier and scaffold for Ortho-ATI® (patients' own cultured tenocytes) was then sutured over the repaired tendon. Both CelGro® and Ortho-ATI® were manufactured at Orthocell’s TGA licensed facility prior to surgical implantation.

Pain and function improvement was reported by the patient at the 12-week post-implantation review.

At six months post-treatment, and a physiotherapy-led strength-based exercise program, the patient reported that pain had settled and was walking without a limp - she had normal function in the hip at 12 months.

A structural improvement in the tendon was confirmed by repeat MRI.

“Exciting potential of Ortho-ATI®”

Treating physician Dr John O’Donnell said: “Gluteal tendinopathy and tendon tears are a common and debilitating injury that is often difficult to treat, especially in older patients who are less likely to benefit from surgery.

“This case study highlights the exciting potential of Ortho-ATI® in combination with CelGro® as a novel therapy for torn gluteal tendons requiring surgical repair.

“I am delighted by these results providing long-lasting improvements, returning the patient to normal function.”

Looking ahead

Orthocell intends to leverage this case report showing CelGro® and Ortho-ATI® results in high-quality tissue repair to further position the medical device and cell therapy as best-in-class regenerative medicine products that can be used on their own or in combination.

Further performance studies are planned to assist in establishing the effectiveness of the combined product.

Quick facts: Orthocell Ltd

Price: 0.49 AUD

ASX:OCC
Market: ASX
Market Cap: $92.51 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Orthocell Ltd named herein, including the promotion by the Company of Orthocell Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Orthocell says Australian reimbursement for CelGro® Dental is important...

Orthocell Ltd's (ASX:OCC) Paul Anderson speaks to Proactive's Andrew Scott soon after receiving notification from the Australian Government Department of Health that CelGro® Dental has been included on the Australian Prostheses List. Inclusion on the prostheses list enables dental practitioners...

4 hours, 11 minutes ago

3 min read